Regulatory aspects in development of stability-indicating methods: A review

Chromatographia

Volumn 72, Issue 1-2, 2010, Pages 1-6

  Sehrawat, Renu ^a   Maithani, Mukesh ^a   Singh, Ranjit ^a  

^a SHOBHIT UNIVERSITY   (India)

Author keywords

Degradation pathways; Regulatory guidelines; Stability indicating assay methods

Indexed keywords

EXCIPIENT;

ANALYTIC METHOD; DRUG DECOMPOSITION; DRUG DEGRADATION; DRUG STABILITY; EXERCISE TEST; FOOD AND DRUG ADMINISTRATION; HYDROLYSIS; INFORMATION; LIQUID CHROMATOGRAPHY; OXIDATION; PHOTODEGRADATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STABILITY INDICATING METHOD; VALIDATION PROCESS;

EID: 77951823733     PISSN: 00095893     EISSN: 16121112     Source Type: Journal    
DOI: 10.1365/s10337-010-1612-z     Document Type: Review

References (38)

1. FDA (1987) Guidelines for Submitting Documentation for the Stability of Human Drugs and Biologics, Center for Drugs and Biologics, FDA, Department of Health and Human Services
2. M Bakshi S Singh 2002 J Pharm Biomed Anal 28 1011 1040 10.1016/S0731-7085(02)00047-X 1:CAS:528:DC%2BD38XktFyiur0%3D (Pubitemid 34607392)
3. Ahuja S, Scypinski S (2005) Handbook of modern pharmaceutical analysis. Elsevier, California, pp 96, 393,448
4. Hong DD, Shah M (2000) In: Carstensen JT, Rhodes T, (eds) Drug stability: principles and practices. Marcel Dekker, New York, pp 329-384
5. M Grover M Gulati S Singh 1998 J Chromatogr B Biomed Sci Appl 708 153 159 10.1016/S0378-4347(97)00654-3 1:CAS:528:DyaK1cXjtVKmsrY%3D (Pubitemid 28239899)
6. U.S. Food and Drug Administration (1987) Drug stability guidelines
7. Ivana I, Ljiljana Z, Mira Z(2006) J Chromatogr A: 209-215
8. Carstensen JT, Rhodes CT (2000) Drug stability: principles and practices. Marcel Dekker, New York
9. NVVSS Raman KA Harikrishna AVSS Prasad KR Reddy K Ramakrishna 2009 J Pharm Biomed Anal 50 797 802 10.1016/j.jpba.2009.06.031 1:CAS:528: DC%2BD1MXhtF2ht7fP
10. Cha J, Joseph S, Weiler R, Lane P (2005) Handbook of modern pharmaceutical analysis. Elsevier, California, p 448
11. FDA (1998) Guidelines for submitting documentation for stability of human drugs and biologics. Food and Drug Administration, Rockville. (www.fda.gov/cder/guidance)
12. FDA (1998) Guidelines for industry, stability testing of drug substances and dosage products (draft guidance). Food and Drug Administration, Rockville
13. WHO (1996), Guidelines for stability testing of pharmaceutical products containing well established drug substances in conventional dosage forms, in WHO expert committee on specifications for pharmaceutical preparations. Technical Report Series 863, World Health Organization, Geneva
14. FDA (1987) Guidelines for submitting documentation for the stability of human drugs and biologics. Food and Drug Administration, Rockville
15. CPMP (1998) Note for guidance on stability testing of existing active substances and related finished products. Committee for Proprietary Medicinal Products, EMEA, London
16. PD T (1997) Stability testing of existing drug substances and products. Therapeutic Products Directorate, Ottawa
17. NR Rao V Nagaraju 2003 J Pharm Biomed Anal 33 335 337 10.1016/S0731-7085(03)00293-0 (Pubitemid 37206463)
18. ICH Q1 A (2003) Stability testing of new drug substances and products
19. ICH Q1B (1996) The tripartite guidelines on photostability testing of new drug substances and products
20. ICH Q2A (R) (1995) Guidelines for industry, text on validation of analytical procedure
21. ICH Q2B (R) (1996) Guidelines on validation of analytical procedure: methodology
22. ICH Q3A (R) (2003) Impurities in new drug substances
23. ICH Q3B (R) (2003) Impurities in new drug products
24. ICH Q3C (1997) The tripartite guidelines on residual solvents
25. ICH Q6A (2000) Guidance on specifications: test procedures and acceptance criteria for new drug substance and products: chemical substances
26. WHO (1997) Quality assurance of pharmaceutical: a compendium of guidelines and related materials, Geneva
27. ICH Q1A (R) (1999) Stability testing of new drug and products (Revised Guidelines)
28. Guidance for industry (2000) Analytical procedures and method validation. U.S. Department of Health and Human Services FDA (www.fda.gov/guidance/index. htm)
29. DW Reynolds 2004 Am Pharm Rev 7 56 61
30. Snyder L, Kirkland JJ, Glajch J (1997) Practical HPLC method development. Wiley-Interscience, New York
31. The United States Pharmacopoeia 25/National Formulary 20 (2002) The United States Pharmacopeial Convention, Inc., Rockville, Maryland, pp 2256
32. ICH Q2B (1997) Validation of analytical procedures: methodology. International conference on harmonization of technical requirements for the registration of drugs for human use. Geneva
33. ICH (2000) Stability testing of new drug substances and products. International conference on harmonization. IFPMA, Geneva, pp 2
34. Yoshika S, Stella VJ (2006) Stability of drugs and dosage forms. Springer Private Limited, New Delhi, pp 5-8
35. Kim HB (2009) Handbook of stability testing in pharmaceutical development. Regulation methodology and best practices. Springer Sciences, New York, p 148
36. ER Garrett K Seyda 1994 J Pharm Sci 83 269 272 10.1002/jps.2600830233 1:CAS:528:DyaK2cXmt1WisA%3D%3D (Pubitemid 24224193)
37. J Run P Tattersall R Lozano P Shah 2006 Am Pharm Rev 9 46 53
38. C Wen 2006 Am Pharm Rev 9 137 140 1:CAS:528:DC%2BD28XhtFGrtLfN